WO2002072822A2 - Als2 gene and amyotrophic lateral sclerosis type 2 - Google Patents
Als2 gene and amyotrophic lateral sclerosis type 2Info
- Publication number
- WO2002072822A2 WO2002072822A2 PCT/CA2002/000147 CA0200147W WO02072822A2 WO 2002072822 A2 WO2002072822 A2 WO 2002072822A2 CA 0200147 W CA0200147 W CA 0200147W WO 02072822 A2 WO02072822 A2 WO 02072822A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- sequence
- nucleic acid
- peptide
- protein
- Prior art date
Links
- 201000008266 amyotrophic lateral sclerosis type 2 Diseases 0.000 title claims abstract description 21
- 101150036028 ALS2 gene Proteins 0.000 title description 37
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 131
- 150000007523 nucleic acids Chemical class 0.000 claims description 95
- 102000039446 nucleic acids Human genes 0.000 claims description 87
- 108020004707 nucleic acids Proteins 0.000 claims description 87
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 74
- 238000000034 method Methods 0.000 claims description 73
- 102000004169 proteins and genes Human genes 0.000 claims description 55
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 40
- 108091034117 Oligonucleotide Proteins 0.000 claims description 35
- 230000035772 mutation Effects 0.000 claims description 35
- 239000002299 complementary DNA Substances 0.000 claims description 31
- 239000012634 fragment Substances 0.000 claims description 31
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 239000013598 vector Substances 0.000 claims description 23
- 239000002773 nucleotide Substances 0.000 claims description 22
- 125000003729 nucleotide group Chemical group 0.000 claims description 22
- 238000003745 diagnosis Methods 0.000 claims description 21
- 230000014509 gene expression Effects 0.000 claims description 19
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 17
- 230000000295 complement effect Effects 0.000 claims description 15
- 230000003321 amplification Effects 0.000 claims description 14
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 14
- 239000000523 sample Substances 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
- 239000012472 biological sample Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 4
- 241000283984 Rodentia Species 0.000 claims description 3
- 230000004071 biological effect Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 108700026220 vif Genes Proteins 0.000 claims 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 abstract description 14
- 108091006109 GTPases Proteins 0.000 abstract description 14
- 230000001105 regulatory effect Effects 0.000 abstract description 11
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 113
- 108020004414 DNA Proteins 0.000 description 50
- 210000004027 cell Anatomy 0.000 description 37
- 238000013518 transcription Methods 0.000 description 30
- 230000035897 transcription Effects 0.000 description 30
- 101000776160 Homo sapiens Alsin Proteins 0.000 description 29
- 238000003752 polymerase chain reaction Methods 0.000 description 23
- 102100032047 Alsin Human genes 0.000 description 19
- 125000000539 amino acid group Chemical group 0.000 description 19
- 230000002950 deficient Effects 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 108020004999 messenger RNA Proteins 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 238000012217 deletion Methods 0.000 description 12
- 230000037430 deletion Effects 0.000 description 12
- 108091005573 modified proteins Proteins 0.000 description 12
- 102000035118 modified proteins Human genes 0.000 description 12
- 230000006870 function Effects 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 10
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 9
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 210000000349 chromosome Anatomy 0.000 description 9
- 210000002569 neuron Anatomy 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 108700024394 Exon Proteins 0.000 description 8
- 238000012408 PCR amplification Methods 0.000 description 8
- 239000012528 membrane Substances 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 108700028369 Alleles Proteins 0.000 description 6
- 108700026244 Open Reading Frames Proteins 0.000 description 6
- 102100039977 Regulator of chromosome condensation Human genes 0.000 description 6
- 101710150974 Regulator of chromosome condensation Proteins 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 101100055414 Homo sapiens ALS2 gene Proteins 0.000 description 5
- 101001077220 Homo sapiens Ras-associated and pleckstrin homology domains-containing protein 1 Proteins 0.000 description 5
- 101100055415 Mus musculus Als2 gene Proteins 0.000 description 5
- 238000000636 Northern blotting Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 210000000278 spinal cord Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 101001104102 Homo sapiens X-linked retinitis pigmentosa GTPase regulator Proteins 0.000 description 4
- 108091092195 Intron Proteins 0.000 description 4
- 102100025208 Ras-associated and pleckstrin homology domains-containing protein 1 Human genes 0.000 description 4
- 238000002105 Southern blotting Methods 0.000 description 4
- 102100040092 X-linked retinitis pigmentosa GTPase regulator Human genes 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 238000010363 gene targeting Methods 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 238000007901 in situ hybridization Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 101100049539 Arabidopsis thaliana VPS9A gene Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 101000995932 Homo sapiens Nucleolar protein 58 Proteins 0.000 description 3
- 108010021466 Mutant Proteins Proteins 0.000 description 3
- 102000008300 Mutant Proteins Human genes 0.000 description 3
- 102100034532 Nucleolar protein 58 Human genes 0.000 description 3
- 238000002944 PCR assay Methods 0.000 description 3
- 101100049541 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) VPS9 gene Proteins 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 102000005912 ran GTP Binding Protein Human genes 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 206010006542 Bulbar palsy Diseases 0.000 description 2
- 102100035933 Calcium-responsive transcription factor Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 2
- 101000715597 Homo sapiens Calcium-responsive transcription factor Proteins 0.000 description 2
- 101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 description 2
- 208000011823 Juvenile amyotrophic lateral sclerosis Diseases 0.000 description 2
- 102100022119 Lipoprotein lipase Human genes 0.000 description 2
- 102100023261 MAGUK p55 subfamily member 4 Human genes 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- KJWZYMMLVHIVSU-IYCNHOCDSA-N PGK1 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)CC1=O KJWZYMMLVHIVSU-IYCNHOCDSA-N 0.000 description 2
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 2
- FNGOXVQBBCMFKV-CIUDSAMLSA-N Pro-Ser-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O FNGOXVQBBCMFKV-CIUDSAMLSA-N 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 210000002226 anterior horn cell Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000037429 base substitution Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 210000001947 dentate gyrus Anatomy 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 102000054766 genetic haplotypes Human genes 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 102000049526 human ALS2 Human genes 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 201000002241 progressive bulbar palsy Diseases 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 210000000449 purkinje cell Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- 101150028074 2 gene Proteins 0.000 description 1
- QPIROHVZMLYRNN-YRNJLPRFSA-N 2-[(3s,6s,9s,12s,15r)-15-[[(2s,3r)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-9-benzyl-6-[(2s)-butan-2-yl]-3-(2-methylsulfanylethyl)-2,5,8,11,14-pentaoxo-1-thia-4,7,10,13-tetrazacyclohe Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCSC)C(=O)SC[C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N1)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)=O)[C@@H](C)CC)C1=CC=CC=C1 QPIROHVZMLYRNN-YRNJLPRFSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 101150001232 ALS gene Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100025422 Bone morphogenetic protein receptor type-2 Human genes 0.000 description 1
- 102100025752 CASP8 and FADD-like apoptosis regulator Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102100026549 Caspase-10 Human genes 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102100033250 Cyclin-dependent kinase 15 Human genes 0.000 description 1
- 206010067477 Cytogenetic abnormality Diseases 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102100028571 Disabled homolog 2-interacting protein Human genes 0.000 description 1
- 101710191399 Disabled homolog 2-interacting protein Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102100040305 Flagellum-associated coiled-coil domain-containing protein 1 Human genes 0.000 description 1
- 102100039676 Frizzled-7 Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 101000934635 Homo sapiens Bone morphogenetic protein receptor type-2 Proteins 0.000 description 1
- 101000914211 Homo sapiens CASP8 and FADD-like apoptosis regulator Proteins 0.000 description 1
- 101000983518 Homo sapiens Caspase-10 Proteins 0.000 description 1
- 101000983528 Homo sapiens Caspase-8 Proteins 0.000 description 1
- 101000944355 Homo sapiens Cyclin-dependent kinase 15 Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000891676 Homo sapiens Flagellum-associated coiled-coil domain-containing protein 1 Proteins 0.000 description 1
- 101000885797 Homo sapiens Frizzled-7 Proteins 0.000 description 1
- 101001042104 Homo sapiens Inducible T-cell costimulator Proteins 0.000 description 1
- 101001033293 Homo sapiens Interleukin enhancer-binding factor 3 Proteins 0.000 description 1
- 101001115423 Homo sapiens MAGUK p55 subfamily member 4 Proteins 0.000 description 1
- 101100077756 Homo sapiens MPP4 gene Proteins 0.000 description 1
- 101001128623 Homo sapiens NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 3 Proteins 0.000 description 1
- 101000601056 Homo sapiens NIF3-like protein 1 Proteins 0.000 description 1
- 101000582320 Homo sapiens Neurogenic differentiation factor 6 Proteins 0.000 description 1
- 101000613984 Homo sapiens Origin recognition complex subunit 2 Proteins 0.000 description 1
- 101001091194 Homo sapiens Peptidyl-prolyl cis-trans isomerase G Proteins 0.000 description 1
- 101000752249 Homo sapiens Rho guanine nucleotide exchange factor 3 Proteins 0.000 description 1
- 101000803747 Homo sapiens Ribosome biogenesis protein WDR12 Proteins 0.000 description 1
- 101000642656 Homo sapiens STE20-related kinase adapter protein beta Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000610729 Homo sapiens Trafficking kinesin-binding protein 2 Proteins 0.000 description 1
- 101000798539 Homo sapiens Transmembrane protein 237 Proteins 0.000 description 1
- 101000802734 Homo sapiens eIF5-mimic protein 2 Proteins 0.000 description 1
- 101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100021317 Inducible T-cell costimulator Human genes 0.000 description 1
- -1 LOC57404 Proteins 0.000 description 1
- 101710137272 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 Proteins 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102100032195 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 3 Human genes 0.000 description 1
- 102100037380 NIF3-like protein 1 Human genes 0.000 description 1
- 102100030589 Neurogenic differentiation factor 6 Human genes 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 102100040608 Origin recognition complex subunit 2 Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 102100022851 Rab5 GDP/GTP exchange factor Human genes 0.000 description 1
- 101710181660 Rab5 GDP/GTP exchange factor Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010053823 Rho Guanine Nucleotide Exchange Factors Proteins 0.000 description 1
- 102100021689 Rho guanine nucleotide exchange factor 3 Human genes 0.000 description 1
- 102100035119 Ribosome biogenesis protein WDR12 Human genes 0.000 description 1
- 102100035929 STE20-related kinase adapter protein beta Human genes 0.000 description 1
- 102100026940 Small ubiquitin-related modifier 1 Human genes 0.000 description 1
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102100040377 Trafficking kinesin-binding protein 2 Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100032480 Transmembrane protein 237 Human genes 0.000 description 1
- 108091007492 Ubiquitin-like domain 1 Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 208000021024 autosomal recessive inheritance Diseases 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 102100035859 eIF5-mimic protein 2 Human genes 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002567 electromyography Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 208000019995 familial amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 102000009543 guanyl-nucleotide exchange factor activity proteins Human genes 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000006122 isoprenylation Effects 0.000 description 1
- 108010012212 junctophilin Proteins 0.000 description 1
- 102000019028 junctophilin Human genes 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000001769 parahippocampal gyrus Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000003900 secondary neuron Anatomy 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
Definitions
- This invention relates to genetic causes of amyotrophic lateral sclerosis of type 2
- ALS Amyotrophic lateral sclerosis
- distal and proximal motor neurons are selectively degenerated 1 . Its cause is ambiguous and its onset is mostly at middle age and thereafter. Its rate of onset is about 2-6 per 100,000 persons and begins with lowering of muscular strength and myoatrophy of wrist muscle as a secondary neuron hindrance resulting in bulbar paralysis symptoms such as atrophy of muscle of limbs, atrophy of tongue, alalia, dysphagia and dyspnea. No therapeutic method has been established yet and most of the afflicted die within five years from onset.
- Juvenile amyotrophic lateral sclerosis of type 2 (“ALS2"; OMIM215100 2 ) is a somatically recessive type hereditary disease. Although the frequency of its onset is rare, muscular convulsion of limbs, face and throat is gradually expressed in persons of teens or twenties and becomes chronic by bulbar paralysis as described above.
- Amyotrophic lateral sclerosis of type 2 has been mapped to the 1.7 cM interval flanked by D2S116 and D2S2237 on human chromosome 2q33 3,4 . Alterations in 391 exons and their flanking regions derived from 43 non-overlapping transcripts have been noted within this interval 5 ' 6 .
- ALS is a very severe disease and there is a need for development of means for its early detection or diagnosis and for treatment. Summary of the Invention
- ALS2 or ALS2CR6 gene a gene associated with amyotrophic lateral sclerosis type 2, termed the ALS2 or ALS2CR6 gene. This gene is expressed in various human tissues including neurons in the brain and spinal cord, and encodes a protein with homology to RanGED and RhoGEF.
- This invention now provides mammalian ALS2 genes and mutant versions thereof as well as peptides (including proteins) encoded by such genes. Also included are fragments and nucleic acids derived from these genes, corresponding peptides, and oligonucleotides suitable for use as amplification primers and/or probes. Antibodies to the peptides of this invention are also provided.
- This invention also provides methods of diagnosis of ALS2 which may include identifying in a patient at risk, an altered ALS2 gene or protein.
- the patient may be tested to characterize one or more mutations in the gene or protein produced.
- Such a mutation may comprise the A 26] del mutation or the AG1548del mutations described herein.
- This invention also provides nucleic acids which correspond to a region of the ALS2 gene, which nucleic acids typically hybridize to at least about 6, at least about 10, at least about 15, at least about 20, or at least about 25 consecutive nucleotides of an ALS2 sequence as described herein, or to complements of such sequences, or to naturally occurring mutants or allelic variants thereof.
- the probes or primers may be chosen to be capable of distinguishing (such as by amplification or hybridization) allelic variants, including the A261del and AG1548del mutations described herein. Such probes or primers may further include a label which is capable of being detected.
- This invention also provides kits for identifying ALS2 genes, including those comprising alleles associated with an ALS2 disease state, wherein the kits may comprise a probe or primer as described herein. The kit may further comprise instructions for using the probes or primers to distinguish alleles as described herein.
- This invention also provides vectors containing nucleic acids of this invention, including vectors adapted for expression of such nucleic acids in a target cell or organism.
- Such vectors may comprise appropriate transcription regulatory elements for directing transcription of the nucleic acids in a target cell or organism.
- Nucleic acids and peptides of this invention may be expressed in bacterial as well as eukaryotic cells, including mammalian cells.
- Such vectors may be adapted to express nucleic acids of this invention in a reverse direction so as to generate anti-sense transcription products.
- This invention also provides non-human mammals comprising a genome in which an ALS2 gene has been mutated, including by deletion.
- a mammal may be a mouse and methods for altering the murine genome such as to produce an ALS2 "knock-out" mouse, are described herein and are known in the art.
- This invention also provides the use of nucleic acids and peptides as disclosed herein for the preparation of medicaments for treatment of ALS2 or in the treatment of ALS2.
- This invention also provides methods of treating patients for ALS2, which methods may comprise testing the patient to diagnose or characterize an ALS2 disease state.
- a patient may be treated for ALS2, for example by administering to the patient or by otherwise providing a native form or functional fragment or derivative of the ALS2 peptide described herein or such other therapeutic agent as which will restore function of the protein in a patient.
- vectors suitable for use in gene therapy and gene therapy methodologies whereby a patient is treated to restore the function of ALS2 by delivering or producing a functional gene for expression in the patient.
- Gene therapy vectors may, for example, be adeno-associated vector, such as those known in the art. General methods for gene therapy are also known in the art.
- This invention includes a human ALS2 gene which is present in human second chromosome q33 region and may code for a GTPase regulatory factor.
- the gene may encode an amino acid sequence of SEQ ID NO:2.
- cDNA synthesized from mRNA that may be transcribed by this gene has a base sequence of SEQ ID NO.T .
- This invention includes a human ALS2 mutated gene which is related to amyotrophic lateral sclerosis of type 2 and codes for a modified protein having an amino acid sequence of SEQ ID NO: 3 or SEQ ID NO:84, by a deficiency of one or two bases of the above human ALS2 gene.
- This invention includes nucleic acids purified from genomic DNA, mRNA or cDNA as well as synthesized nucleic acids.
- This invention includes oligonucleotides which hybridize to ALS2 genes and variants thereof, preferably under stringent conditions.
- This invention includes kits comprising oligonucleotides or oligonucleotide primer sets which may be used to carry out amplification of ALS2 encoded nucleic acids, for example by the polymerase chain reaction (PCR).
- PCR polymerase chain reaction
- This invention includes oligonucleotide probes which hybridize to the regions containing base deficient sites (A261del and AG1548del) in ALS2 under stringent conditions.
- This invention includes oligonucleotide primer sets which carry out a PCR amplification of the region containing a base deficient site in ALS2 as described herein.
- a specific example of this primer set is a pair of synthetic oligonucleotides comprising the base sequences of SEQ ID NO: 6 and NO: 7 or a pair of synthetic oligonucleotides comprising the base sequences of SEQ ID NO: 8 and NO: 9.
- This invention includes recombinant vectors comprising the above nucleic acids and cells transcribed by said recombinant vectors.
- This invention includes a GTPase regulatory factor or a GEF which is characterized in being an expression product of an ALS2 gene as described herein.
- Embodiments of such GTPase regulatory factors of GEF 's are recombinant proteins produced by the transformed cells transformed according to this invention..
- This invention includes a peptide comprising an amino acid sequence having continuous 5 or more acid amino residues in the first to the 46th amino acid sequence in SEQ ID NO: 2 and also a peptide comprising an amino acid sequence having continuous 5 or more acid amino residues in the 47th to the 1657th amino acid sequence in SEQ ID NO:
- These peptides may be used for production of antibodies.
- This invention also provides a modified protein which may be an expression product of a mutant human ALS2 gene and which comprises the amino acid sequence of SEQ ID NO: 3.
- An embodiment of this modified protein is a recombinant protein produced by a transformed cell.
- This invention includes an antibody which recognizes peptides (including proteins) as disclosed herein.
- Embodiments of this antibody are an antibody which is prepared using a peptide according to this invention as an antigen, including a peptide comprising an amino acid sequence having continuous 5 or more acid amino residues in the first to the 46th amino acid sequence in SEQ ID NO: 2 and also an antibody which is prepared using a peptide comprising an amino acid sequence having continuous 5 or more acid amino residues in the 47th to the 1657th amino acid sequence in SEQ ID NO: 2 as an antigen.
- This invention furthermore provides methods for the diagnosis of amyotrophic lateral sclerosis of type 2 which is characterized in detecting ALS2 mutated genes.
- An embodiment of this method for the diagnosis it that genomic DNA of the cells of a person to be diagnosed is subjected to a PCR amplification using a primer set comprising a pair of synthetic oligonucleotides comprising the base sequences of SEQ ID NO: 6 and NO: 7 or a pair of synthetic oligonucleotides comprising the base sequences of SEQ ID NO: 8 and NO: 9, the resulting DNA fragments are treated with a restriction enzyme Narl and the said person where each of the DNA fragments is divided into two fragments is judged to be suffering from amyotrophic lateral sclerosis of type 2.
- This invention also provides a method for the diagnosis of amyotrophic lateral sclerosis of type 2 which is characterized in that the transcribed product of an ALS2 gene or mutated gene is detected.
- the transcribed product is cDNA or mRNA of the gene of an ALS2 mutated gene or the modified protein expressed by the said mutated gene.
- An embodiment of the case of detection of the modified protein is a method for the detection of the protein where the antibody recognizing the first to the 46th amino acid sequences in SEQ ID NO: 2 reacts but the antibody recognizing the 47th to the 1657th amino acid sequence region in SEQ ID NO: 2 does not react.
- this invention provides a mouse ALS2 gene which may have an amino acid sequence of SEQ ID NO:5 as well as nucleic acids derived therefrom including nucleic acids synthesized or purified from genomic DNA, mRNA or cDNA of the mouse gene or a complementary sequence thereof.
- This invention also provides a gene-defective non-human mammal such as a rodent, preferably a mouse, where function of an ALS2 gene is substantially deficient. Also provided are tissues of such a mouse.
- the human ALS2 gene according to this invention is a genomic gene which has 33 introns and 34 exons, exists in a genomic DNA of 80.3 kb adjacent to a polymorphic DNA marker D2S2309 in human second chromosome q 33 region (refer to Fig. 1) and codes for a human GTPase regulatory factor having an amino acid sequence of SEQ ID NO:2.
- a human GTPase regulatory factor having an amino acid sequence of SEQ ID NO:2.
- its cDNA has a base sequence of SEQ ID NO: 1.
- This invention provides an isolated nucleic acid that codes for a peptide having at least about 75, 80, 85, 90, 95, 97 or 100% identity to all of an amino acid sequence selected from the group consisting of: SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:5; SEQ ID NO:
- amino acids 372-1657 of SEQ ID NO:84 amino acids 372-1657 of SEQ ID NO:2. Also provided are the peptides encoded by these nucleic acids.
- This invention also provides an isolated nucleic acid consisting essentially of a nucleotide sequence having at least about 75, 80, 85, 90, 95, 97 or 100% identity to all of a nucleotide sequence or a complementary sequence thereof, selected from the group consisting of: SEQ ID NO:l; SEQ ID NO:4; nucleotides 124-5094 of SEQ ID NO:l; nucleotides 1225-5094 of SEQ ID NO:l; and, nucleotides 124-5076 of SEQ ID NO:4. Also provided are the peptides encoded by these nucleic acids.
- nucleic acids of this invention may be joined to a second nucleic acid not naturally associated with the nucleic acid of this invention.
- second nucleic acid is not part of an ALS2 gene and is not directly joined to an ALS2 gene in the genome of a mammal.
- This invention also provides an oligonucleotide of 6 to 75 nucleotides, wherein the oligonucleotide hybridizes to a nucleic acid of this invention or a complementary sequence thereof, under stringent conditions.
- An oligonucleotide of this invention may be joined to a label, which is any moiety suitable for detectable labelling of the nucleic acid or for binding of the nucleic acid to a non-nucleic acid moiety.
- This invention also provides a peptide consisting essentially of a sequence of at least 5 contiguous amino acids from a sequence selected from the group consisting of: amino acids 1-46 of SEQ ID NO:2; amino acids 47-1657 of SEQ ID NO:2; SEQ ID NO:3; amino acids 43-49 of SEQ ID NO:3; SEQ ID NO:84; and amino acids 476 to 545 of SEQ ID NO:84.
- These peptides are useful, for example in raising antibodies of this invention and for investigating the function of the ALS2 protein.
- This invention also provides a non-human mammal comprising a mutated gene, wherein the gene but for the mutation would encode a protein having at least about 75, 80, 85, 90, 95, 97 or 100% sequence identity to all of SEQ ID NO:2 or SEQ ID NO:5.
- This invention also provides a method for the diagnosis of amyotrophic lateral sclerosis type 2 in a patient, comprising detecting the presence of a mutation in a gene that encodes a protein having at least about 75, 80, 85, 90, 95, 97 or 100% sequence identity to SEQ ID NO:2 in a patient or a biological sample from a patient.
- This invention also provides a method for the diagnosis of amyotrophic lateral sclerosis type 2, comprising detecting the presence or absence of a protein having at least about 75, 80, 85, 90, 95, 97 or 100% sequence identity to all of SEQ ID NO:2 in a patient or a biological sample from a patient.
- This invention also provides a method for the diagnosis of amyotrophic lateral sclerosis type 2, comprising detecting the presence or absence of a protein having at least about 75, 80, 85, 90, 95, 97 or 100% sequence identity to all of SEQ ID NO:3 or SEQ ID NO: 84 in a patient or a biological sample from a patient.
- sequences may be compared to determine the presence of mutations; oligonucleotides may be used to detect hybridization to nucleic acids of the patient; amplification of nucleic acids of the patient may be performed; proteins of the patient may be contacted with antibodies of this invention; or proteins produced in the patient may be evaluated for the function of ALS2 protein.
- This invention also provides a method of treatment of amyotrophic lateral sclerosis type 2, comprising administering a peptide, a nucleic acid, or a pharmaceutical composition comprising the peptide or nucleic acid to a patient in need thereof, wherein the peptide comprises an amino acid sequence having at least about 75, 80, 85, 90, 95, 97 or 100% identity to SEQ ID NO:2 or a fragment thereof, and wherein the nucleic acid codes for said peptide.
- This invention also provides a method of treatment of amyotrophic lateral sclerosis type 2, comprising administering a composition to a patient in need thereof, wherein the composition mimics the biological activity of the peptide of SEQ ID NO. 2 or a fragment thereof.
- This invention also provides the use of a peptide or a nucleic acid for preparation of a medicament for treatment of amyotrophic lateral sclerosis type 2, wherein the peptide comprises an amino acid sequence having at least about 75, 80, 85, 90, 95, 97 or 100% identity to SEQ ID NO:2 or a fragment thereof, and the nucleic acid codes for said peptide.
- isolated with reference to a nucleic acid or peptide means that a nucleic acid is separate from the genome of a cell, a peptide is separate from a cell but does not mean that the subject matter has been obtained from a genome or a cell.
- nucleic acids and peptides of this invention may be synthesized using conventional techniques.
- sequence identity may for example be at least 75%, at least 90% or at least 95%.
- Optimal alignment of sequences for comparisons of identity may be conducted using a variety of algorithms, such as the local homology algorithm of Smith and Waterman, 1981, Adv. Appl. Math 2: 482, the homology alignment algorithm of Needleman and Wunsch, 1970, J. Mol. Biol. 48:443, the search for similarity method of Pearson and Lipman, 1988, Proc. Natl. Acad. Sci.
- Nucleic acid sequences of the invention may in some embodiments be substantially identical, such as substantially identical gene targeting substrates and target sequences.
- the substantial identity of such sequences may be reflected in percentage of identity when optimally aligned that may for example be greater than 50%, 80% to 100%, at least 80%, at least 90% or at least 95%, which in the case of gene targeting substrates may refer to the identity of a portion of the gene targeting substrate with a portion of the target sequence, wherein the degree of identity may facilitate homologous pairing and recombination and/or repair.
- An alternative indication that two nucleic acid sequences are substantially identical is that the two sequences hybridize to each other under moderately stringent, or preferably stringent, conditions.
- Hybridization to filter-bound sequences under moderately stringent conditions may, for example, be performed in 0.5 M NaHPO 4 , 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.2 x SSC/0.1% SDS at 42°C (see Ausubel, et al. (eds), 1989, Current Protocols in Molecular Biology, Vol. 1 , Green Publishing
- hybridization to filter-bound sequences under stringent conditions may, for example, be performed in 0.5 M NaHPO 4 , 7% SDS, 1 mM EDTA at 65°C, and washing in 0.1 x SSC/0.1% SDS at 68°C (see Ausubel, et al. (eds), 1989, supra).
- Hybridization conditions may be modified in accordance with known methods depending on the sequence of interest (see Tijssen, 1993, Laboratory Techniques in Biochemistry and Molecular Biology — Hybridization with Nucleic Acid Probes, Part I, Chapter 2 "Overview of principles of hybridization and the strategy of nucleic acid probe assays", Elsevier, New York).
- stringent conditions are selected to be about 5°C lower than the thermal melting point for the specific sequence at a defined ionic strength and pH. It is well known in the art that some modifications and changes can be made in the structure of a polypeptide without substantially altering the biological function of that peptide, to obtain a biologically equivalent polypeptide.
- LPL S447X therapeutics may include peptides that differ from a portion of the wild-type LPL sequence by conservative amino acid substitutions.
- conservative amino acid substitutions refers to the substitution of one amino acid for another at a given location in the peptide, where the substitution can be made without loss of function.
- substitutions of like amino acid residues can be made, for example, on the basis of relative similarity of side-chain substituents, for example, their size, charge, hydrophobicity, hydrophilicity, and the like, and such substitutions may be assayed for their effect on the function of the peptide by routine testing.
- conserved amino acid substitutions may be made where an amino acid residue is substituted for another having a similar hydrophilicity value (e.g., within a value of plus or minus 2.0), where the following hydrophilicity values are assigned to amino acid residues (as detailed in United States Patent No.
- conserved amino acid substitutions may be made where an amino acid residue is substituted for another having a similar hydropathic index (e.g., within a value of plus or minus 2.0).
- each amino acid residue may be assigned a hydropathic index on the basis of its hydrophobicity and charge characteristics, as follows: He (+4.5); Val (+4.2); Leu (+3.8); Phe (+2.8); Cys (+2.5); Met (+1.9); Ala (+1.8); Gly (-0.4); Thr (-0.7); Ser (-0.8); Trp (-0.9); Tyr (-1.3); Pro (-1.6); His (-3.2); Glu (-3.5); Gin (-3.5); Asp (-3.5); Asn (-3.5); Lys (-3.9); and Arg (-4.5).
- conserved amino acid substitutions may be made where an amino acid residue is substituted for another in the same class, where the amino acids are divided into non-polar, acidic, basic and neutral classes, as follows: non-polar: Ala, Val, Leu, He, Phe, Trp, Pro, Met; acidic: Asp, Glu; basic: Lys, Arg, His; neutral: Gly, Ser, Thr, Cys, Asn, Gin, Tyr.
- Figure 1 is a transcription map of 3Mb region of human chromosome 2q33 including an ALS2 candidate region.
- the white open rectangle is between D2S116 to D2S2237 2 ' 3 .
- Positions of 7 STS markers, 12 polymorphic DNA markers and 42 independent transcription units are shown.
- Polarity of 38 transcription units are shown by arrows.
- the location of the ALS2 gene is designated "ALS2CR6" which term may be used interchangeably for ALS2 below.
- Figure 2 shows a process for the detection of ALS2 associated mutations, "a" is an example of the Tunisian and Kuwaiti ALS2 families.
- Genotypes of the members constituting a family is shown based on previously reported results 3 ' 4 , "b” shows the result of sequence determination of mutation (A261de ⁇ ) in genomic DNA of the Tunisian ALS2 family.
- Patient 10797 is A261del of a homozygotic type and the carrier 10784 is a heterozygotic type.
- the sequence determination was carried out for PCR products, "c” shows the results of determination of mutation (AG1548del) in the genomic DNA in the Kuwaiti ALS2 family. Sequence of the reverse strand of exon 5 in the region of interest are shown.
- Individual 18279 is a normal sibling, who is unaffected by ALS2 and carries two normal haplotypes.
- the box in this sequence indicates the position of the bases deleted in affected members.
- Individual 18281 is an unaffected parent who carries one disease haplotype. The overlapping normal and mutated sequences are shown.
- Individual 18275 is affected and the figure shows a homozygous CT deletion in the reverse strand of exon 5. The position of the deleted bases is indicated by the arrow.
- the corresponding forward sequence and coded normal amino acids and novel amino acids produced by frameshifting are indicated, "d” shows segregation of the A261del mutation in the Tunisian ALS2 family. The presence of the deletion was assayed by the digestion with Narl, which only cuts mutated gene product.
- FIG. 3 shows northern blot analysis of the ALS2 (ALS2CR6) mRNA.
- ALS2CR6 northern blot analysis of the ALS2 (ALS2CR6) mRNA.
- a a northern blot containing 2 ⁇ g of poly A + mRNA of many adult human tissues is hybridized with exon 4 of ALS2 cD A.
- RNA sample is hybridized with human ⁇ -actin cDNA for confirmation of the property and the comparative load of RNA.
- size of the ALS2 transcript is shown.
- northern blot containing 10 ⁇ g of total RNA obtained normal whole brain and 20 ⁇ g of total RNA obtained from lymphocytes of patients and healthy persons (10788 persons) was hybridized to exon 4 of the ALS2 cDNA.
- the right panel shows an agarose gel electrophoresis of an RNA sample.
- Figure 4 is a comparison of amino acid sequences in human ALS2CR6 and mouse homolog mALS2CR6. The same residues are shown by frames. There are shown the position of the additional three amino acid residues of the Tunisian mutant protein (starting from the 47th amino acid residue), the position of the 25 amino acid residues (starting from the 372nd residue) of a short variant part of the ALS2 gene and the position of the additional 70 amino acid residues of the Kuwaiti mutant protein (starting from the 476 th residue).
- Figure 5 shows an expression of ALS2 mRNA in brain and spinal cord of adult mouse
- "a” is an arrow-like whole image of an RNA/RNA in situ hybridization using an antisense ALS2 riboprobe
- "b” is a control image using a sense strand probe.
- Significant expression was noted in neurons of hippocampus and dentate gyrus (c and g), Purkinje cells of cerebellum (d and h), neurons of cerebral cortex (e and i) and cinerea of spinal cord including anterior horn cells (f and j).
- a scale bar shows a length of 10 ⁇ m.
- Figure 6 is a result of an amino acid sequence analysis
- "a” is a schematic chart of domains and motifs in normal and mutated ALS2 protein.
- RCC1 is a regulatory factor for chromosome condensation
- DH is a homologous domain to Dbl
- PH is a pleckstrin- homologous domain
- MORN is membrane structure and recognition nexus
- VPS9 is a vacuole protein for discrimination of 9 domains
- "b” is comparison of amino acid sequences of RCC1 repeat-containing regions for human ALS2 (hALS2CR6), mouse ALS2 (mALS2CR6), human (h) RCC1 , human (h) RPGR and mouse (m) RPGR.
- the amino acid residues shown by open frames are the same. conserveed amino acid residues are abundantly contained as well. Positions of the seven blades corresponding to RCC1 are shown according to the literature .
- Figure 7 is a chart that compares the wild type human, mouse, and short human variant of the ALS2 proteins and the coding products of the A261del (Tunisian) and AG1548del (Kuwaiti) mutations.
- the locus of a 1.7 cM region specified by microsatellite markers D2S116 and D2S2237 of a human second chromosome q 33 region has been mapped 3 ' 4 .
- the inventors previously prepared a physical map on the basis of YAC/BAC/PAC of 3Mb genomic region covering the candidate region in Figure l 5 ' 6 .
- Sequences of cDNA clones and EST's have now been analyzed and 42 non-duplicated transcription units including 10 new genes mapped.
- 411 pairs in of primers were designed depending upon genomic DNA of 14 persons of a family of ALS2 (Fig. 2a) and 6 normal control persons having no kinship with the former was amplified by PCR. Seventy-seven base sequence polymorphs of introns or exons were identified by determining the sequence for all of the PCR products. Among them, a gene having base deletions related to onset of ALS2 was identified.
- the ALS2 gene also includes restriction regions and regulatory regions (promoter/enhancer, suppressor, etc.) which function in expression of protein which is coded thereby. Such restriction and regulation regions are useful for clarifying the functions of the ALS2 gene product as a GEF or a GTPase regulatory factor.
- This ALS2 gene may, for example, by isolated by screening a human genome library using pure polynucleotide or oligonucleotide comprising a base sequence of SEQ ID NO: 1 or a partial sequence thereof as a probe.
- the resulting genomic gene may be amplified by commonly used genetic amplifying methods such as, for example, a PCR (polymerase chain reaction) method, an NASBN (nucleic acid sequence based amplification) method, a TMA (transcription-mediated amplification) method or an SDA (strand displacement amplification) method.
- a pure polynucleotide may also be prepared from this ALS2 genomic gene, mRNA transcribed by this gene or cDNA synthesized from mRNA.
- cDNA may be synthesized using poly(A) + RNA extracted from human cells as a template. The human cells may be either those excised from human body by operation, etc. or incubated cells.
- cDNA may be synthesized by known methods (Mol. Cell Biol., 2, 161-170, 1982; J. Gene, 25, 263-269, 1983; Gene, 150, 243-250, 1994).
- the cDNA prepared as such has a base sequence of SEQ ID NO: 1.
- Those polynucleotides may be used for recombinant expression of a human GTPase regulatory factor.
- the oligonucleotides of this invention are DNA fragments or RNA fragments which hybridize to the above-mentioned ALS2 or the above-mentioned nucleic acids under stringent conditions.
- stringent conditions means a condition whereby a specific hybrid formation of target with a probe is made possible by salt concentration, concentration of organic solvent (such as formamide), or temperature condition during hybridization and washing steps. Methods are described in U. S. Patent No. 6,100,037.
- a primer set of this invention is typically a pair of oligonucleotides for amplification of ALS2 gene or related nucleic acids.
- Such a primer set may be designed on the basis of the base sequence of SEQ ID NO: 1, synthesized and subjected to purification using known methods. Size (base numbers) of the primer preferably is 15-40 bases or more preferably, 15-30 bases which specificity anneal with a template DNA. However, when LA (long accurate) PCR is carried out, it is effective to use primers in excess of 30 bases.
- a pair (two) primers comprising sense strand (5 '-terminal side) and antisense strand (3 '-terminal side) should not be complementary.
- a self-complementary sequence is to be avoided in a primer to prevent the formation of a hairpin structure.
- the GC content should be about 50% and occurrence of GC- rich or AT-rich regions in a primer should be avoided. Since an annealing temperature is dependent upon Tm (melting temperature), primers having Tm of 55-65°C are chosen so as to prepare a PCR product having a high specificity. The final concentration of the primer used in PCR should be about 0.1 to about 1 ⁇ M. It is possible to use commercially available software for designing a primer including the Oligo software [manufactured by National Bioscience Inc. (U. S. A.)] and GenetyxTM software [manufactured by Software Development KK (Japan)].
- Mutated ALS2 genes may be obtained by a method where a DNA library prepared from cells of a patient thought to be suffering from ALS2 is screened with a probe which hybridizes to a region containing mutant (e.g. a base deficient site) under a stringent condition.
- Pure polynucleotide DNA fragment or RNA fragment
- an ALS2 mutated gene comprises a nucleic acid where the 261st base a of SEQ ID NO: 1 is deficient.
- Such a polynucleotide may be used for recombinant production of ALS2 modified protein or for diagnosis of ALS2.
- a primer set for a PCR amplification of ALS2, including various regions having base deficient sites in mutated ALS2 is (for example) a pair of synthetic oligonucleotides comprising base sequences of SEQ ID NO: 6 and NO: 7.
- This primer set is capable of a PCR amplification of the region (339 bp) including exon 3 and introns before and after that in the ALS2 gene.
- Another primer set may be composed of synthetic oligonucleotides comprising base sequences of SEQ ID NO: 8 and NO: 9 and is capable of PCR amplification of exons 2-4 (302 bp) of the ALS2 gene using RNA as a template.
- Any PCR product not cleaved by the restriction enzyme Narl is derived from the normal ALS2 gene but PCR products derived from a mutated ALS 2 gene may be cleaved by Narl to give two fragments (Fig. 2c).
- a recombinant vector of this invention may be a cloning vector or an expression vector.
- Vectors will be constructed depending upon the type of the polynucleotide as an insert or upon the object for use. For example, when an ALS2 protein or a modified protein thereof is produced using cDNA or its ORF region as an insert, there may be used an expression vector for an in vitro transcription or an expression suitable for each of prokaryotic cells such as Escherichia coli and Bacillus subtilis and eukaryotic cells such as yeast, insect cells and mammalian cells.
- prokaryotic cells such as Escherichia coli and Bacillus subtilis
- eukaryotic cells such as yeast, insect cells and mammalian cells.
- a genomic DNA of the ALS2 gene or a mutated gene thereof is used as an insert
- a BAC bacterial artificial chromosome
- cosmid vector bacterial artificial chromosome
- Such recombinant vectors are also useful, for example, as probes for diagnosis of chromosome abnormality by hybridization including fluorescent in situ hybridization (FISH).
- FISH fluorescent in situ hybridization
- a nucleic acid derived from a normal ALS2 gene may be recombined in a virus vector such as adenovirus or the like and the product may be used for genetic therapy.
- a transformed cell of this invention may be a prokaryotic cell such as Escherichia coli and Bacillus subtilis or an eukaryotic cell such as from yeast, insects, and mammals.
- cells such as blood stem cells
- Such transformed cells may be prepared by introducing a recombinant vector into cells by means of known methods such as electroporation, calcium phosphate method, liposome method and DEAE dextran method.
- a peptide of this invention may be an expression product of a normal ALS2 gene or an expression product of a mutated ALS2 gene.
- the normal gene product is a GTPase transcription factor or GEF having an amino acid sequence of SEQ ID NO: 2.
- Peptides of this invention are useful as immunogens for the preparation of an antibody, as target molecules for the development of therapeutic agents for ALS2, etc. These peptides may be prepared by methods involving isolating peptides from the cells of healthy persons or patients suffering from ALS2. Methods of chemical synthesis on the basis of a desired amino acid sequence from SEQ ID NO:2 or SEQ ID NO:3, etc. and (preferably) by production and isolation or purification from the above-mentioned transformed cells.
- Such transformed cells are incubated and isolation and purification are carried out for the culture by, for example, means of treatment with a modifier such as urea or with a surface-active agent, ultrasonic wave treatment, enzymatic digestion, precipitation by salting out or by solvent, dialysis, centrifugal separation, ultrafiltration, gel filtration, SDS-PAGE, isoelectric electrophoresis, ion exchange chromatography, hydrophobic chromatography, affinity chromatography and reversed phase chromatography.
- a modifier such as urea or with a surface-active agent
- ultrasonic wave treatment such as urea or with a surface-active agent
- enzymatic digestion precipitation by salting out or by solvent
- dialysis centrifugal separation
- ultrafiltration gel filtration
- SDS-PAGE isoelectric electrophoresis
- ion exchange chromatography hydrophobic chromatography
- affinity chromatography affinity chromatography
- reversed phase chromatography such as Amberlite chromatography
- the protein expressed in cells may be subjected to various kinds of modifications in the cells after being translated. Accordingly, modified proteins are also included in the coverage of the protein of this invention. Examples of the modification after translation as such are elimination of N-terminal methionine, N-terminal acetylation, addition of sugar chain, limited decomposition by intracellular protease, myristoylation, isoprenylation and phosphorylation.
- An antibody of this invention is a polyclonal antibody or monoclonal antibody which recognizes a peptide of this invention.
- Examples include an antibody prepared using a peptide comprising an amino acid sequence of continuous 5 amino acid residues or more of the first to the 46th amino acid sequence in SEQ ID NO: 2 as an antigen and an antibody prepared using a peptide comprising an amino acid sequence of continuous 5 amino acid residues or more of the 47th to the 1657th amino acid sequence in SEQ ID NO: 2 as an antigen.
- an antibody prepared using a peptide comprising an amino acid sequence of continuous 5 amino acid residues or more of the first to the 46th amino acid sequence in SEQ ID NO: 2 as an antigen and an antibody prepared using a peptide comprising an amino acid sequence of continuous 5 amino acid residues or more of the 47th to the 1657th amino acid sequence in SEQ ID NO: 2 as an antigen.
- the antibody of this invention includes all molecules which are able to bind to an epitope of an ALS2 protein or other peptide of this invention, and all of Fab, F(ab') 2 , Fv fragments, etc. thereof.
- Such an antibody can be obtained from serum after an animal is immunized using ALS2 derived protein or peptide as an antigen.
- the above expression vectors for eukaryotic cells may be introduced into muscle or skin of animals by injection or particle gun and then serum is collected therefrom. Examples of animals that may be used are mouse, rat, rabbit, goat, chicken, etc.
- B cells collected from the spleen of an immunized animal are fused with myeloma cells to produce a hybridoma, it is possible to produce monoclonal antibodies.
- the diagnostic method of this invention is one in which an ALS2 mutated gene or a transcription product of an ALS2 mutated gene is detected whereby the risk of onset of ALS2 may be estimated.
- Particularly amenable are persons of known ALS2 families although diagnosis is not limited thereto.
- Genomic DNA of a person to be diagnosed may be subjected to a PCR amplification using any of the above-mentioned primer sets or other oligonucleotides of this invention.
- the resulting DNA fragment may be treated with one or more restriction enzymes such as Narl, and the person to be diagnosed where the DNA fragment is cleaved into fragments different from cleaving product produced from a person not suffering from ALS2 is indicative of a patient suffering from ALS2 or a person with some risk of ALS2 in view of the presence of a mutation in the ALS2 gene.
- ALS2 mutated genes by (for example) an allele- specific oligonucleotide probe method, an oligonucleotide ligation assay method, a PCR- SSCP method, a PCR-CFLP method, a PCR-PHFA method, an invader method, an RCA (rolling circle amplification) method and a primer oligo base extension method.
- an allele- specific oligonucleotide probe method for example, an allele- specific oligonucleotide probe method, an oligonucleotide ligation assay method, a PCR- SSCP method, a PCR-CFLP method, a PCR-PHFA method, an invader method, an RCA (rolling circle amplification) method and a primer oligo base extension method.
- diagnosis may be carried out by determining the sequence of mRNA of the person to be diagnosed or cDNA thereof. It is also possible to carry out the diagnosis in such a manner that an ALS2 gene of a person to be diagnosed or cDNA thereof is recombined with an expression vector, transfected to cells and the expression product thereof measured.
- Expression products of normal and mutant ALS2 genes may be assessed by measurement of molecular weight.
- the frame shift caused by deletion of one base in normal ALS2 gene whereupon the modified protein is changed to a low-molecular protein (SEQ ID NO: 3) comprising the first to the 46th amino acid residues of SEQ ID NO: 2 and three amino acid residues (Pro-Ser-Glu) newly coded by the frame shift results in a product having a molecular weight easily comparable to naturally occurring gene products of the normal ALS2 gene.
- diagnosis may be also carried out by the above antibody provided by this invention in which the ALS2 modified protein reacts with an antibody recognizing (for example) the first to the 46th amino acid sequence in SEQ ID NO: 2 or a region comprising amino acids 43-49 of SEQ ID NO:3, but does not react with an antibody recognizing the 47th to the 1657th amino acid sequence region in SEQ ID NO: 2.
- Antibodies specific for amino acids 476 to 545 of SEQ ID NO:84 as compared to any of the amino acids of SEQ ID NO:2 could be similarly used for diagnosis of the AG1548del. Diagnosis using antibodies may, for example, be carried out with an ELIZA method.
- the mouse ALS2 gene of this invention is a mouse genomic gene isolated as a homolog of the human ALS2 gene and which codes for a mouse ALS2 protein comprising an amino acid sequence of SEQ ID NO: 5. Its cDNA has a base sequence of SEQ ID NO: 4. This gene may be used for the preparation of a "knock-out” mouse. Such a "knock-out" mouse can be prepared by known gene targeting methods
- a DNA fragment of the mouse ALS2 gene including the initiation codon of the gene is modified whereupon a defective DNA fragment which deletes expression of the ALS2 gene is obtained.
- This defective DNA fragment is used for the preparation of a targeting vector for introduction of the modification into a mouse totipotent cell (ES cell) according to known methods (such as the method described in Science, 244: 1288-1292, 1989).
- genomic DNA comprising the ALS2 gene is substituted or inserted with a resistant gene to a cytotoxin to prepare a recombinant plasmid DNA possessing the defective gene having a sequence homologous to the genomic DNA of the ALS2 gene at both terminals (the targeting vector).
- the resistant gene it is also possible for the resistant gene to be connected to a sequence such as PGK1 promoter and PGK1 polyadenylation signal for controlling the expression.
- the genomic DNA site of the ALS2CR6 gene which is substituted with or inserted by resistant gene be a genomic DNA region containing an exon region containing an initiation codon.
- target vectors there are no particular limitations on such target vectors except that it will have a sequence which is homologous to genomic DNA of the ALS2 gene and a resistance sequence or other sequence useful for cell sorting (such as diphtheria toxin A gene and thymidine kinase gene of herpes virus).
- a promoter and enhancer may be appropriately combined and used.
- the targeting vector is then introduced into an ES (embryonic stem) cell according to known methods (e.g. Nature, 292: 154-156, 1981). Such methods include electric pulse, a liposome and calcium phosphate. When recombination efficiency of the gene to be introduced is of concern, the electric pulse methods is preferred.
- DNA in each of the ES cells into which gene is introduced is extracted and, by means of a southern blot analysis or a PCR assay, cells are selected in which a homologous gene recombination has taken place between the wild type ALS2 gene existing on the chromosome and the introduced defective ALS2 gene fragment resulting in placement of the defective gene fragment in the chromosome.
- An ES cell having a defective gene prepared above may be injected into a blastocyst of a wild type animal and chimera-embryos obtained which are transplanted to the uterus of a preliminary parent. Resulting progeny are selected for the ALS2 defective gene and bred. Selection may be carried out by checking the difference in the color of hair or by extraction of DNA from a part of the body (such as the tail end) followed by conducting a southern blot analysis, a PCR assay after extraction of DNA, etc.
- a southern blot analysis, a PCR assay or the like may be carried out using the DNA extracted from a part of the body (such as the tail end) as a material to identify a heterozygote into which the ALS2 defective gene is introduced.
- a heterozygote possessing the ALS2 defective gene which is stable in all generative cells and somatic cells may be bred to produce progeny in which the ALS2 gene is completely T ocked-out".
- An animal prepared as such may be used for analysis of function of ALS2 gene in onset of ALS 2 and for screening of therapeutic drugs or development of therapeutic methods as an ALS2 model animal.
- ALS2 Sixteen cases including 8 individuals suffering from the disease obtained from a Tunisian consanginous ALS2 family (literature 2) were analyzed.
- the characteristic of ALS2 is a progressive convulsion of muscles of the limbs and the face accompanied by distal myoatrophy of the hand and the foot. Age of onset is between 3 and 10 years age (literature 2). According to biopsy of nerves and muscles and also to electromyography test, there was confirmed deletion of distal motor neuron (literature 2).
- ALS2 was clearly an autosomal recessive inheritance.
- GDB Transcription map Genome Data Base (GDB) (http://www.gdbwww.gdb.org) and UniGene
- genomic DNA sequence data open to the public in GenBank data base was compared with the sequence of cDNA using a Sequencer Version 3.0 (Gene Codes Corporation) program according to the descriptions of BLAST (literature 28) and literatures (5 and 6). 1-4.
- Exon and intron/exon boundaries were subjected to a PCR amplification.
- ExTaq polymerase (Takara) was used and a cycle of 95 °C for 15 seconds, 60°C for 30 seconds and 72°C for 30 seconds was repeated for 35 times whereby about 50 mg of genomic DNA were amplified by a PCR.
- an RT- PCR was carried out. Total RNA from lymphocytes of four patients of a family of ALS2 and two carriers was isolated. Total RNA extracted from a healthy human brain was purchased from Clontech.
- An RT-PCR was carried out using a Superscript pre- amplification system (Gibco-BRL) according to the protocol of the manufacturer.
- the oligonucleotide primer for such a PCR was designed using Primer 3.0 (http://www- genome.wi.mit.edu). Table 1 lists the primers used for amplification of ALS2 (ALS2CR6).
- CD 10 CALSlllex007 467 5'-CAATOATOTACTGATOAACCAaC-3' 30 5 ' -CCTGATGGTTTAATGGTGGG-3 • CO 31 11 CA Slll ⁇ xOO ⁇ 348 S'-OCACATaOCAACAaOTTAAO-S' 32 5 • - ⁇ cc ⁇ ocAQAATAAcae ⁇ a-3 • 33 12 CALSlll ⁇ xOl 426 5 ' -CCCCTACCACTCCCTTTACC-3 ⁇ 34 5 * -CCAOTGOCTAATAGTACCTGTCC-3 • 35 13 CA Slllex02 480 5 ' -TGOATGCATOATTCATTTCC-3 ' 36 5 ' -TCCTTGGCTTTCCAAATGTC-3 • 37 m 14 CALSlll ⁇ x03 462 5 * -CTATCCTaGOGTCTCTCTOCTO-3 • 38 5 * -TOCTATCOAAATOOTTGCTO-3 • 39 co 15 CALSlll ⁇ x04 290 5 '
- a DNA sequence of a PCR product of exon was determined.
- the DNA sequence of a PCR product of exon was analyzed using the same oligonucleotide as a primer.
- the sequence in the data base open to the public was compared with the DNA sequence obtained from patients, carriers and healthy persons and changes in the nucleotide were discriminated.
- TCCCATACCTGACCTTCCAC-3' (SEQ ID NO: 7).
- primers for the RT-PCR of exons 2-4 there were used 5'-CTTGATAGACTTTCTGTAAAGAAG-3' (SEQ ID NO: 8) and 5'-GGCTACTTGGACAAATCTCCACTG-3' (SEQ ID NO: 9).
- Decomposed product with Narl was separated by 1.5% agarose gel.
- Antisense and sense cRNA probes were prepared from two mouse cDNA clones m2- as and m2-s. Those mouse cDNA clones covered a part of mouse mALS2CR6 cDNA (from the 1732nd to the 2685th bases of SEQ ID NO: 4; 954 bp) and inserted into pCR2.1 (Invitrogen) in an opposite direction.
- the probes were prepared according to the protocol of the manufacturer (Roche Molecular Biochemicals) by an in vitro transcription reaction where digoxigenin-labelled UTP and T7 polymerase were mixed. Preparation of the sample and method for the in situ hybridization were in accordance with the literature (29).
- the inventors have prepared a physical map on the basis of YAC/BAC/PAC of genomic region of 3 Mb covering a complete candidate region to ALS2 (literatures 5 and 6). Sequences of EST and cDNA clone were analyzed within a broad area and, at the same time, this physical map was used for the mapping of 43 independent transcription units including previously analyzed 18 genes (KIAA0005, CLKl, PP1L3, ORC2L, NDUFB3, CFLAR, CASP10, CASP8, FZD7, NOP5, UBL1, BMPR2, FLJ10881, LOC57404, AIP-1, CD28, CTLA4 and AILIM) and new 10 full-length transcription products (ALS2CR1, ALS2CR2, ALS2CR3, ALS2CR4, ALS2CR5/MPP4, ALS2CR6, ALS2CR7, ALS2CR8, ALS2CR9 and ALS2CR12). Those genetic sequences were present in the locus of ALS2 (Fig. 1). [00
- Juvenile ALS2 is rare and has a sign that, in teens and twenties, muscular convulsion of limbs, face and throat gradually expresses. Since ALS2 is recessively hereditary, it is predicted that this ALS2 disease may take place by a loss of a functional mutation. Big deletion or translocation in the ALS2 locus was investigated by a mapping of STS/EST content on the basis of a PCR and a southern blot analysis but that was not detected. After that, small deletion or base substitution in exon or intron-exon boundary was investigated. In order to detect those mutations, each gene was analyzed and an intron/exon boundary thereof was determined. Until now, 395 exons have been identified from 42 genes.
- NOP5 intron 2 tatctc(D9aattct ⁇ CQ ⁇
- NOP5 intron 6 gttttg(TTG 2ttttta ⁇ (TTG
- ALS2CR6 gene contains 33 introns and 34 exons and is present in a genomic DNA of 80.3 kb adjacent to a polymorphic DNA marker D2S2309 (Fig. 1). Transcription polarity of the ALS2CR6 gene is in the direction of central body from telomere.
- An ALS2CR6 transcription product (mRNA) has a full length of 6394 bp (SEQ ID NO: 1) having a single open reading frame (ORF) with a length of 4974 nucleotides (124-5,097 nt) and codes for a protein of 184 KDa comprising 1,657 amino acid residues.
- Polyadenylated estimated signal (AATAAA: 6,375-6,380 nt) and poly(A) region are clear.
- a short ALS2CR6 transcription product in a full length of 2,651 bp having 1,191 bp ORF coding for a 396 amino acid sequence was identified as well.
- This short variant splices a 5 '-donor site after exon 4 and, as a result, a stop codon is formed after 25 amino acid residues of intron 4.
- 2 transcription products of about 6.5 kb and 2.6 kb were identified in many adult human tissues by a northern blot analysis (Fig. 3a). Except the liver where short transcription products are mostly expressed, both transcription products showed the similar expression pattern.
- mALS2CR6 a mouse homolog of ALS2CR6 was isolated and named mALS2CR6.
- a transcription product of mALS2CR6 is in a full length of 6,349 bp (SEQ ID NO: 4) having one ORF of 4,956 bp (124-5,076 nt) and codes for a protein of 183 kDa comprising 1651 amino acids (SEQ ID NO: 5).
- the ORF as a whole is well reserved in a DNA level (87% same) and a protein level (91 % same; 94% similar; Fig. 4) between human being and mouse and it is suggested that ALS2CR6 gene is a gene which is well reserved in mammals.
- mALS2CR6 transcription product In order to check the localization property of expression of mALS2CR6 transcription product in the brain and the spinal cord of mouse, an in situ hybridization using riboprobe corresponding to a part of mALS2CR6 cDNA was carried out. The result was that, as shown in Fig. 5, the mALS2CR6 transcription products were expressed in various levels in nerve cells from the brain to the spinal cord, especially in neurons of hippocampal and dentate gyrus, cerebellar Purkinje cells, neurons of cerebral cortex and spinal cinerea including anterior horn cells. In addition, a significant expression was noted in neurons of olfactory bulb, basal nucleus and cranial nerve nucleus as well.
- Human ALS2CR6 protein showed many interesting properties (Fig. 6a). The first property is present in a region of A-terminal side of ALS2CR6 and it showed a high homology to RCC1 (regulatory factor for concentrating the chromosome; literature 7) and RPGR (GTPase for pigmentary retinitis; literature 8)(Fig. 8). RCC1 and RPGR protein acts as a guanine nucleotide exchange factor (GEF) for GTPase like Ran.
- GEF guanine nucleotide exchange factor
- ALS2CR6 has a Dbl -homologous (DH) domain and a pleckstrin-homologous (PH) domain and both domains are typical domains noted in RhoGEF protein (literatures 9 and 10).
- VPS9 domain is noted in a C-terminal region as well.
- VPS9 domain is noted in many GEF including Vps9 (literature 11) and Rabex-5 (literature 12) and each is said to mediate the selection of vacuole protein and the phagocytic transportation.
- Two MORN motives comprising 14 amino acids (literature 13) were noted as well.
- ALS2CR6 acts as a regulatory factor/activator of Ran-related GTPase, regulates the formation of membrane and acts in a (membrane) transportation of cells including neurons.
- a transcription product of mutated ALS2CR6 gene is transcribed from chromosomes of the patient (Fig. 2c) and produces a modified protein comprising 49 amino acids having three new residues (Pro-Ser-Glu) at C-terminal (Fig. 6a). Since this modified protein has no functional domain corresponding to ALS2CR6 protein, it seems to make the inherent function lost. Accordingly, the A261del mutation noted in this ALS2CR6 is related to the fact that ALS2 is recessively hereditary.
- ALS2CR6 gene is the second ALS gene succeeding to the determination of role of copper-zinc superoxide desmutase (SDS-1) in ALS. Mutation of SOD-1 is related to the form of tardive autosomal dominance (literature 23).
- ALS2CR2, and ALS2CR3 in the juvenile amyotrophic lateral sclerosis (ALS2) critical region at chromosome 2q33-q34: candidate genes for ALS2.
- Vps9p is a guanine nucleotide exchange factor involved in vesicle-mediated vacuolar protein transport. J. Biol. Chem. 274, 15284-15291 (1999).
- Rho GTPase and a putative RhoGEF mediate a signaling pathway for the cell shape changes in Drosophila gastrulation.
- RPGR retinitis pigmentosa GTPase regulator
- ALS4 autosomal dominant juvenile amyotrophic lateral sclerosis
- NAIP neuronal apoptosis inhibitory protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002437960A CA2437960A1 (en) | 2001-02-12 | 2002-02-12 | Als2 gene and amyotrophic lateral sclerosis type 2 |
US10/467,909 US20040137450A1 (en) | 2001-04-16 | 2002-02-12 | Als2 gene and amyotrophic lateral sclerosis type 2 |
JP2002571877A JP2005525079A (en) | 2001-02-12 | 2002-02-12 | ALS2 gene and amyotrophic lateral sclerosis type 2 |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26772301P | 2001-02-12 | 2001-02-12 | |
US60/267,723 | 2001-02-12 | ||
JP2001116973A JP2002306179A (en) | 2001-04-16 | 2001-04-16 | Als2cr6 gene and method for diagnosing type 2 amyotrophic lateral sclerosis |
JP2001-116973 | 2001-04-16 | ||
US31835201P | 2001-09-12 | 2001-09-12 | |
US60/318,352 | 2001-09-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002072822A2 true WO2002072822A2 (en) | 2002-09-19 |
WO2002072822A3 WO2002072822A3 (en) | 2003-04-24 |
Family
ID=27346540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2002/000147 WO2002072822A2 (en) | 2001-02-12 | 2002-02-12 | Als2 gene and amyotrophic lateral sclerosis type 2 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP2005525079A (en) |
CA (1) | CA2437960A1 (en) |
WO (1) | WO2002072822A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170157197A1 (en) * | 2015-06-26 | 2017-06-08 | Genervon Biopharmaceuticals, LLC | Methods of using gm604 in modulating als disease biomarkers leading to prognosis and therapeutic treatment for als disease |
WO2018080573A1 (en) * | 2016-10-28 | 2018-05-03 | Massachusetts Institute Of Technology | Crispr/cas global regulator screening platform |
CN111593031A (en) * | 2020-05-07 | 2020-08-28 | 海南波莲水稻基因科技有限公司 | Rice ALS mutant gene, plant transgenic screening vector pCALSm3 containing gene and application thereof |
-
2002
- 2002-02-12 WO PCT/CA2002/000147 patent/WO2002072822A2/en active Application Filing
- 2002-02-12 JP JP2002571877A patent/JP2005525079A/en not_active Withdrawn
- 2002-02-12 CA CA002437960A patent/CA2437960A1/en not_active Abandoned
Non-Patent Citations (8)
Title |
---|
DATABASE EMBL [Online] 1 January 1990 (1990-01-01) retrieved from EMBL Database accession no. P13569 XP002220641 * |
DATABASE EMBL [Online] 29 September 2000 (2000-09-29) retrieved from EMBL Database accession no. AK023024 XP002220502 * |
GALLET X ET AL: "PREDICTION OF THE ANTIGENIC SITES OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN BY MOLECULAR MODELLING" PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 8, no. 8, 1 August 1995 (1995-08-01), pages 829-834, XP000565688 ISSN: 0269-2139 * |
HADANO S ET AL: "A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2." NATURE GENETICS. UNITED STATES OCT 2001, vol. 29, no. 2, October 2001 (2001-10), pages 166-173, XP002220497 ISSN: 1061-4036 -& DATABASE EMBL [Online] 1 December 2001 (2001-12-01) retrieved from EMBL Database accession no. Q96Q42 XP002222645 -& DATABASE EMBL [Online] 1 December 2001 (2001-12-01) retrieved from EMBL Database accession no. Q920R0 XP002222646 -& DATABASE EMBL [Online] 2 October 2001 (2001-10-02) retrieved from EMBL Database accession no. AB053305 XP002222647 -& DATABASE EMBL [Online] 2 October 2001 (2001-10-02) retrieved from EMBL Database accession no. AB053307 XP002222648 * |
HADANO S ET AL: "Cloning and characterization of three novel genes, ALS2CR1, ALS2CR2, and ALS2CR3, in the juvenile amyotrophic lateral sclerosis (ALS2) critical region at chromosome 2q33-q34: candidate genes for ALS2." GENOMICS. UNITED STATES 15 JAN 2001, vol. 71, no. 2, 15 January 2001 (2001-01-15), pages 200-213, XP002220500 ISSN: 0888-7543 * |
ROEPMAN R ET AL: "The retinitis pigmentosa GTPase regulator (RPGR) interacts with novel transport-like proteins in the outer segments of rod photoreceptors." HUMAN MOLECULAR GENETICS. ENGLAND 1 SEP 2000, vol. 9, no. 14, 1 September 2000 (2000-09-01), pages 2095-2105, XP002220499 ISSN: 0964-6906 * |
SHAW P J: "Genetic inroads in familial ALS." NATURE GENETICS. UNITED STATES OCT 2001, vol. 29, no. 2, October 2001 (2001-10), pages 103-104, XP002220501 ISSN: 1061-4036 * |
YANG Y ET AL: "The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis." NATURE GENETICS. UNITED STATES OCT 2001, vol. 29, no. 2, October 2001 (2001-10), pages 160-165, XP002220498 ISSN: 1061-4036 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170157197A1 (en) * | 2015-06-26 | 2017-06-08 | Genervon Biopharmaceuticals, LLC | Methods of using gm604 in modulating als disease biomarkers leading to prognosis and therapeutic treatment for als disease |
US10632169B2 (en) * | 2015-06-26 | 2020-04-28 | Genervon Biopharmaceuticals, LLC | Methods of using GM604 in modulating ALS disease biomarkers leading to prognosis and therapeutic treatment for ALS disease |
WO2018080573A1 (en) * | 2016-10-28 | 2018-05-03 | Massachusetts Institute Of Technology | Crispr/cas global regulator screening platform |
CN111593031A (en) * | 2020-05-07 | 2020-08-28 | 海南波莲水稻基因科技有限公司 | Rice ALS mutant gene, plant transgenic screening vector pCALSm3 containing gene and application thereof |
CN111593031B (en) * | 2020-05-07 | 2022-04-08 | 海南波莲水稻基因科技有限公司 | Rice ALS mutant gene, plant transgenic screening vector pCALSm3 containing gene and application thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2002072822A3 (en) | 2003-04-24 |
CA2437960A1 (en) | 2002-09-19 |
JP2005525079A (en) | 2005-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8962269B2 (en) | Spinal muscular atrophy diagnostic methods | |
CA2554380C (en) | Mecp2e1 gene | |
CA2268771C (en) | Polymorphisms and new genes in the region of the human hemochromatosis gene | |
US20030190639A1 (en) | Genes involved in intestinal inflamatory diseases and use thereof | |
JP3449419B2 (en) | Long QT syndrome gene encoding KVLQT1 and its association with minK | |
JP2004508835A (en) | Human osteoporosis gene | |
US6524819B1 (en) | Down syndrome critical region 1-like proteins | |
US20040067226A1 (en) | Gene responsible for stargardt-like dominant macular dystrophy | |
WO2002072822A2 (en) | Als2 gene and amyotrophic lateral sclerosis type 2 | |
US5700926A (en) | Molecular cloning of the anhidrotic ectodermal dysplasia gene | |
US20040137450A1 (en) | Als2 gene and amyotrophic lateral sclerosis type 2 | |
JP3517988B2 (en) | Human McCard-Joseph disease-related protein, cDNA and gene encoding the protein, vector containing the DNA or gene, host cell transformed with the expression vector, method for diagnosing and treating McCard-Joseph disease | |
US6310182B1 (en) | Compositions for the diagnosis and treatment of Chediak-Higashi syndrome | |
US20040086913A1 (en) | Human genes and gene expression products XVI | |
KR100811926B1 (en) | Compositions useful for regulating parkin gene activity | |
AU767263B2 (en) | Nucleic acids encoding human CIDE-B protein and polymorphic markers thereof | |
US20050064411A1 (en) | Novel gene nedl-1 | |
JP4083790B2 (en) | Fukuyama-type congenital muscular dystrophy-causing protein | |
WO2009127211A1 (en) | Methods and kits for determining spinal dysmyelination | |
US6670465B1 (en) | Retinal calcium channel (alpha)1F-subunit gene | |
JP4083287B2 (en) | Fukuyama-type congenital muscular dystrophy-causing protein | |
US20040242468A1 (en) | Gene involved in mineral deposition and uses thereof | |
WO2003000111A2 (en) | Human ugrp (uteroglobin-related protein) 1 promoter and its use | |
US20040110937A1 (en) | Xin-related proteins | |
CA2203070A1 (en) | Chromosome 6 gene and gene products related to alzheimer's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2437960 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002571877 Country of ref document: JP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10467909 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |